We recently published a list of Top 10 Trending AI Stocks to Watch in November. In this article, we are going to take a look ...
Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, ...
The Princess of Wales continued to return to her royal duties at the Festival of Remembrance after completing chemotherapy ...
Fifteenth acquisition in 2024: Mutares has signed an agreement to acquire Natura sp. z o.o. from Pelion S.A.
As George Ford’s last-second drop goal sailed to the right of the posts, one word sprang to my mind ... all standing together ...
Maharashtra's political parties are leveraging technology to engage voters in the upcoming election. While NCP utilizes AI ...
Hosted on MSN4d
These 5,000-year-old seals might have paved the way for the invention of writing (and the birth of history)In the dusty city states of ancient Mesopotamia, long before the advent of written language, mysterious symbols etched into ...
The last human sacrifices carried out in Rome—beyond considering the ludi gladiatorii as an acceptable adaptation of the ...
Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
Hudson holds 35% of the refrigerant reclamation market, benefiting from the AIM Act's phase down of virgin HFC production.
Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024 ...
Naronapride is currently being studied in a Phase 2 clinical trial for gastroparesis in collaboration ... Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback